These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 10914706)
1. Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Cheung NK; Guo HF; Heller G; Cheung IY Clin Cancer Res; 2000 Jul; 6(7):2653-60. PubMed ID: 10914706 [TBL] [Abstract][Full Text] [Related]
2. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cheung NK; Cheung IY; Canete A; Yeh SJ; Kushner B; Bonilla MA; Heller G; Larson SM Cancer Res; 1994 Apr; 54(8):2228-33. PubMed ID: 8174131 [TBL] [Abstract][Full Text] [Related]
3. Correlation of anti-idiotype network with survival following anti-G(D2) monoclonal antibody 3F8 therapy of stage 4 neuroblastoma. Cheung NK; Guo HF; Cheung IY Med Pediatr Oncol; 2000 Dec; 35(6):635-7. PubMed ID: 11107135 [TBL] [Abstract][Full Text] [Related]
4. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy. Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906 [TBL] [Abstract][Full Text] [Related]
5. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. Cheung NK; Kushner BH; Cheung IY; Kramer K; Canete A; Gerald W; Bonilla MA; Finn R; Yeh SJ; Larson SM J Clin Oncol; 1998 Sep; 16(9):3053-60. PubMed ID: 9738575 [TBL] [Abstract][Full Text] [Related]
6. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. Gruber R; van Haarlem LJ; Warnaar SO; Holz E; Riethmüller G Cancer Res; 2000 Apr; 60(7):1921-6. PubMed ID: 10766181 [TBL] [Abstract][Full Text] [Related]
7. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891 [TBL] [Abstract][Full Text] [Related]
8. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Foon KA; Sen G; Hutchins L; Kashala OL; Baral R; Banerjee M; Chakraborty M; Garrison J; Reisfeld RA; Bhattacharya-Chatterjee M Clin Cancer Res; 1998 May; 4(5):1117-24. PubMed ID: 9607568 [TBL] [Abstract][Full Text] [Related]
9. 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: a phase II study. Cheung NK; Kushner BH; Yeh SJ; Larson SM Prog Clin Biol Res; 1994; 385():319-28. PubMed ID: 7972227 [No Abstract] [Full Text] [Related]
10. Neuroblastoma. Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111 [TBL] [Abstract][Full Text] [Related]
11. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Cheung NK; Modak S Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes in patients with stage IV neuroblastoma. Escobar MA; Grosfeld JL; Powell RL; West KW; Scherer LR; Fallon RJ; Rescorla FJ J Pediatr Surg; 2006 Feb; 41(2):377-81. PubMed ID: 16481255 [TBL] [Abstract][Full Text] [Related]
14. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154 [TBL] [Abstract][Full Text] [Related]
15. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. Cheung NK; Sowers R; Vickers AJ; Cheung IY; Kushner BH; Gorlick R J Clin Oncol; 2006 Jun; 24(18):2885-90. PubMed ID: 16682723 [TBL] [Abstract][Full Text] [Related]
16. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Foon KA; John WJ; Chakraborty M; Sherratt A; Garrison J; Flett M; Bhattacharya-Chatterjee M Clin Cancer Res; 1997 Aug; 3(8):1267-76. PubMed ID: 9815809 [TBL] [Abstract][Full Text] [Related]
17. Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. Cheung NK; Cheung IY; Kramer K; Modak S; Kuk D; Pandit-Taskar N; Chamberlain E; Ostrovnaya I; Kushner BH Int J Cancer; 2014 Nov; 135(9):2199-205. PubMed ID: 24644014 [TBL] [Abstract][Full Text] [Related]
18. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma. Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK Clin Cancer Res; 1998 Sep; 4(9):2135-9. PubMed ID: 9748131 [TBL] [Abstract][Full Text] [Related]
19. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. Cheung IY; Lo Piccolo MS; Kushner BH; Cheung NK J Clin Oncol; 2003 Oct; 21(20):3853-8. PubMed ID: 14551304 [TBL] [Abstract][Full Text] [Related]
20. Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. Kushner BH; Kramer K; LaQuaglia MP; Modak S; Cheung NK Med Pediatr Oncol; 2003 Dec; 41(6):508-15. PubMed ID: 14595707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]